Efficient Repression of Endogenous Major Histocompatibility Complex Class II Expression through Dominant Negative CIITA Mutants Isolated by a Functional Selection Strategy

REFERENCES

• Andre, I., A. Gonzalez, B. Wang, J. Katz, C. Benoist, and D. Mathis. 1996. Checkpoints in the progression of autoimmune disease: lessons from diabetesmodels. Proc. Natl. Acad. Sci. USA 93:2260–2263.
   PubMed Web of Science ®Google Scholar
• Attardi, L. D., D. Von Seggern, and R. Tjian. 1993. Ectopic expression ofwild-type or a dominant-negative mutant of transcription factor NTF-1 disruptsnormal Drosophila development. Proc. Natl. Acad. Sci. USA 90:10563–10567.
   PubMedGoogle Scholar
• Barnstable, C. J., W. F. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. Williams, and A. Ziegler. 1978. Production of monoclonal antibodies togroup A erythrocytes, HLA and other human cell surface antigens—newtools for genetic analysis. Cell 14:9–20.
   PubMed Web of Science ®Google Scholar
• Benoist, C., and D. Mathis. 1990. Regulation of major histocompatibilitycomplex class-II genes: X, Y and other letters of the alphabet. Annu. Rev.Immunol. 8:681–715.
   PubMed Web of Science ®Google Scholar
• Bontron, S., V. Steimle, C. Ucla, and B. Mach. 1997. Two novel mutations inthe MHC class II transactivator CIITA in a second patient from MHC classII deficiency complementation group A. Hum. Genet. 99:541–546.
   PubMedGoogle Scholar
• Bowman, T., H. Symonds, L. Gu, C. Yin, M. Oren, and T. Van Dyke. 1996. Tissue-specific inactivation of p53 tumor suppression in the mouse. GenesDev. 10:826–835.
   PubMedGoogle Scholar
• Brent, R., and M. Ptashne. 1985. A eukaryotic transcriptional activatorbearing the DNA specificity of a prokaryotic repressor. Cell 43:729–736.
   PubMed Web of Science ®Google Scholar
• Brown, J. A., X. F. He, S. D. Westerheide, and J. M. Boss. 1996. Characterizationof the expressed CIITA allele in the class II MHC transcriptionalmutant RJ2.2.5. Immunogenetics 43:88–91.
   PubMedGoogle Scholar
• Calnan, B. J., S. Szychowski, F. K. Chan, D. Cado, and A. Winoto. 1995. Arole for the orphan steroid receptor Nur77 in apoptosis accompanying antigeninduced negative selection. Immunity 3:273–282.
   PubMedGoogle Scholar
• Charron, D. J., and H. O. McDevitt. 1979. Analysis of HLA-D regionassociatedmolecules with monoclonal antibody. Proc. Natl. Acad. Sci. USA 76:6567–6571.
   PubMedGoogle Scholar
• De Lerma Barbaro, A., S. Sartoris, G. Tosi, M. Nicolis, and R. S. Accolla. 1994. Evidence for a specific post-transcriptional mechanism controlling theexpression of HLA-DQ, but not -DR and -DP, molecules. J. Immunol. 153:4530–4538.
   PubMedGoogle Scholar
• Diedrichs, M., and D. J. Schendel. 1989. Differential surface expression ofclass II isotypes on activated CD4 and CD8 cells correlates with levels oflocus-specific mRNA. J. Immunol. 142:3275–3280.
   PubMedGoogle Scholar
• Durand, B., P. Sperisen, P. Emery, E. Barras, M. Zufferey, B. Mach, and W. Reith. 1997. RFXAP, a novel subunit of the RFX DNA binding complex ismutated in MHC class II deficiency. EMBO J. 16:1045–1055.
   PubMedGoogle Scholar
• Glimcher, L. H., and C. J. Kara. 1992. Sequences and factors: a guide toMHC class-II transcription. Annu. Rev. Immunol. 10:13–49.
   PubMed Web of Science ®Google Scholar
• Gönczy, P., W. Reith, E. Barras, B. Lisowska-Grospierre, C. Griscelli, M. R. Hadam, and B. Mach. 1989. Inherited immunodeficiency with a defect in amajor histocompatibility complex class II promoter-binding protein differs inthe chromatin structure of the HLA-DRA gene. Mol. Cell. Biol. 9:296–302.
   PubMedGoogle Scholar
• Griscelli, C., B. Lisowska-Grospierre, and B. Mach. 1993. Combined immunodeficiencywith defective expression in MHC class II genes, p. 141–154. In F. S. Rosen and M. Seligman (ed.), Immunodeficiencies. Harwood Academic Publishers, Chur, Switzerland.
   Google Scholar
• Hachiya, M., A. Chumakov, C. W. Miller, M. Akashi, J. Said, and H. P. Koeffler. 1994. Mutant p53 proteins behave in a dominant, negative fashionin vivo. Anticancer Res. 14:1853–1859.
   PubMedGoogle Scholar
• Helbig, H., K. L. Kittredge, A. G. Palestine, M. Coca Prados, and R. B. Nussenblatt. 1991. Gamma-interferon induces differential expression ofHLA-DR, -DP and -DQ in human ciliary epithelial cells. Graefes. Arch. Clin. Exp. Ophthalmol. 229:191–194.
   PubMedGoogle Scholar
• Herskowitz, I. 1987. Functional inactivation of genes by dominant negativemutations. Nature 329:219–222.
   PubMed Web of Science ®Google Scholar
• Janeway, C. A., K. Bottomly, P. Conrad, S. Conzen, B. Jones, J. Kaye, M. Katz, L. McVay, D. B. Murphy, and J. Tite. 1984. Quantitative variation inIa antigen expression plays a central role in immune regulation. Immunol. Today 5:55–60.
   Google Scholar
• Katz, J. D., B. Wang, K. Haskins, C. Benoist, and D. Mathis. 1993. Followinga diabetogenic T cell from genesis through pathogenesis. Cell 74:1089–1100.
   PubMed Web of Science ®Google Scholar
• Kobe, B., and J. Deisenhofer. 1995. Proteins with leucine-rich repeats. Curr. Opin. Struct. Biol. 5:409–416.
   PubMed Web of Science ®Google Scholar
• Lalle, P., C. MoyretLalle, Q. Wang, J. M. Vialle, C. Navarro, B. Bressac dePaillerets, J. P. Magaud, and M. Ozturk. 1995. Genomic stability and wildtypep53 function of lymphoblastoid cells with germ-line p53 mutation. Oncogene 10:2447–2454.
   PubMedGoogle Scholar
• Lloyd, A., N. Yancheva, and B. Wasylyk. 1991. Transformation suppressoractivity of a Jun transcription factor lacking its activation domain. Nature 352:635–638.
   PubMedGoogle Scholar
• Mach, B., V. Steimle, E. Martinez-Soria, and W. Reith. 1996. Regulation ofMHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14:301–331.
   PubMed Web of Science ®Google Scholar
• Maurer, D. H., J. H. Hanke, E. Mickelson, R. R. Rich, and M. S. Pollack. 1987. Differential presentation of HLA-DR, DQ, and DP restriction elementsby interferon-gamma-treated dermal fibroblasts. J. Immunol. 139:715–723.
   PubMed Web of Science ®Google Scholar
• O’Hare, P., and G. Williams. 1992. Structural studies of the acidic transactivationdomain of the Vmw65 protein of herpes simplex virus using 1HNMR. Biochemistry 31:4150–4156.
   PubMedGoogle Scholar
• Otten, L. A., V. Steimle, S. Bontron, and B. Mach. Unpublished data.
   Google Scholar
• Perlmutter, R. M., and J. Alberola-Ila. 1996. The use of dominant-negativemutations to elucidate signal transduction pathways in lymphocytes. Curr. Opin. Immunol. 8:285–290.
   PubMedGoogle Scholar
• Platt, J. L. 1996. Xenotransplantation: recent progress and current perspectives. Curr. Opin. Immunol. 8:721–728.
   PubMedGoogle Scholar
• Reith, W., S. Satola, C. Herrero Sanchez, I. Amaldi, B. Lisowska-Grospierre, C. Griscelli, M. R. Hadam, and B. Mach. 1988. Congenital immunodeficiencywith a regulatory defect in MHC class II gene expression lacks aspecific HLA-DR promoter binding protein, RF-X. Cell 53:897–906.
   PubMed Web of Science ®Google Scholar
• Reith, W., V. Steimle, and B. Mach. 1995. Molecular defects in the barelymphocyte syndrome and the regulation of MHC class II genes. Immunol. Today 16:539–546.
   PubMedGoogle Scholar
• Riley, J. L., S. D. Westerheide, J. A. Price, J. A. Brown, and J. M. Boss. 1995. Activation of class II MHC genes requires both the X box and the class IItransactivator (CIITA). Immunity 2:533–543.
   PubMedGoogle Scholar
• Seipel, K., O. Georgiev, and W. Schaffner. 1992. Different activation domainsstimulate transcription from remote (‘enhancer’) and proximal (‘promoter’)positions. EMBO J. 11:4961–4968.
   PubMedGoogle Scholar
• Silacci, P., A. Mottet, V. Steimle, W. Reith, and B. Mach. 1994. Developmentalextinction of major histocompatibility complex class II gene expressionin plasmocytes is mediated by silencing of the transactivator geneCIITA. J. Exp. Med. 180:1329–1336.
   PubMed Web of Science ®Google Scholar
• Steimle, V., B. Durand, E. Barras, M. Zufferey, M. R. Hadam, B. Mach, and W. Reith. 1995. A novel DNA binding regulatory factor is mutated in primaryMHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1021–1032.
   PubMedGoogle Scholar
• Steimle, V., and B. Mach. Unpublished data.
   Google Scholar
• Steimle, V., L. A. Otten, M. Zufferey, and B. Mach. 1993. Complementationcloning of an MHC class II transactivator mutated in hereditary MHC classII deficiency (or bare lymphocyte syndrome). Cell 75:135–146.
   PubMed Web of Science ®Google Scholar
• Steimle, V., C. Siegrist, A. Mottet, B. Lisowska-Grospierre, and B. Mach. 1994. Regulation of MHC class II expression by interferon-g mediated by thetransactivator gene CIITA. Science 265:106–109.
   PubMed Web of Science ®Google Scholar
• Tabor, S., and C. C. Richardson. 1985. A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proc. Natl. Acad. Sci. USA 82:1074–1078.
   PubMed Web of Science ®Google Scholar
• Takebe, Y., M. Seiki, J. Fujisawa, P. Hoy, K. Yokota, K. Arai, M. Yoshida, and N. Arai. 1988. SRapromoter: an efficient and versatile mammaliancDNA expression system composed of the simian virus 40 early promoterand the R-U5 segment of human T-cell leukemia virus type 1 long terminalrepeat. Mol. Cell. Biol. 8:466–472.
   PubMed Web of Science ®Google Scholar
• Ucla, C., W. Reith, and B. Mach. Unpublished data.
   Google Scholar
• Wang, P., M. Reed, Y. Wang, G. Mayr, J. E. Stenger, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1994. p53 domains: structure, oligomerization, and transformation. Mol. Cell. Biol. 14:5182–5191.
   PubMed Web of Science ®Google Scholar
• Watson, A. J., F. H. Bach, R. Demars, and I. S. Trowbridge. 1983. Detectionof a novel human class II HLA antigen. Nature 304:358–361.
   PubMedGoogle Scholar
• Wilkinson, M. 1988. RNA isolation: a mini-prep method. Nucleic Acids Res16:10933.
   Google Scholar
• Yamada, K., D. H. Sachs, and H. DerSimonian. 1995. Human anti-porcinexenogeneic T cell response. Evidence for allelic specificity of mixed leukocytereaction and for both direct and indirect pathways of recognition. J. Immunol. 155:5249–5256.
   PubMed Web of Science ®Google Scholar
• Zhou, H., and L. H. Glimcher. 1995. Human MHC class II gene transcriptiondirected by the carboxyl terminus of CIITA, one of the defective genes intype II MHC combined immune deficiency. Immunity 2:545–553.
   PubMedGoogle Scholar
• Ziegler, A., H. Götz, J. Heinig, C. Muller, F. P. Thinnes, B. Uchanska-Ziegler, and P. Wernet. 1986. Analysis by sequential immunoprecipitations of thespecificities of the monoclonal antibodies Tü22, Tü34, Tü35, Tü36, Tü37,Tü39, Tü43, Tü58, and Yd1/63. Hlk directed against human HLA class IIantigens. Immunobiology 171:77–92.
   Google Scholar